Cardinal Health, Inc.
Analysis
Cardinal's fiscal 2026 was a step-change: EPS up by a third on roughly $5 billion of free cash flow, with all five segments growing. Fiscal 2027 is guided to a slower, more normal year, so the question is how much of last year was the business and how much was one-off. How much of fiscal 2026's profit growth came from acquisitions?
- Specialty is now the engine, and it grew far faster than planned.
Specialty revenue passed $50 billion and grew about 25% in fiscal 2026, far above its old mid-teens pace. Fiscal 2027 planning assumes it settles back to mid-teens, so last year's lift is not assumed to repeat. How much of specialty's growth came from acquisitions rather than demand?
- The smaller, higher-margin businesses now move the whole company.
at-Home, Nuclear and OptiFreight grew profit faster than drug shipping again, and Cardinal keeps buying more of the same. These units earn more per dollar of sales, so their growth lifts profit faster than revenue.
- Fiscal 2027's guide marks a clear step down in growth.
Pharma profit growth is guided to high single digits in fiscal 2027, down from over 20% last year — customer wins are being lapped and Medicare price cuts repeat yearly. Management calls it strong demand, not last year's outsized demand. How much did the Medicare price changes cut pharma revenue last year?
- Fee-based distribution economicsThe bull case is that Cardinal earns a fixed fee for moving drugs rather than a percentage of the price, so profit can grow even when the prices of the drugs it handles fall.
- Specialty and MSO mixThe bull case is that specialty distribution, physician practice platforms and manufacturer services grow faster and earn more per dollar than the core business, lifting overall profit.
- GMPD turnaround progressThe bull case is that the medical products unit has moved from losses to reliable profit as Cardinal Health brand products take share and operations are simplified.
- Outsized demand fadingThe bear case is that the last year's growth came partly from unusually strong demand that management explicitly refuses to assume repeats in its guidance.
- IRA price reductionsThe bear case is that capped drug prices shrink the revenue Cardinal collects fees on and pressure the economics of the physician practices it serves.
- Customer concentrationThe bear case is that a single customer supplies a large share of revenue, so a contract loss or consolidation among buyers would be hard to replace.
| Politician | Transaction | Amount | Traded | Filed |
|---|---|---|---|---|
Donald Trump Republican · Executive | Purchase | ≥$15K | Jun 12 | Aug 22 |
Donald Trump Republican · Executive | Sale | ≥$15K | May 11 | Jul 1 |
Donald Trump Republican · Executive | Purchase | ≥$15K | May 5 | Jul 1 |
Alan Armstrong Republican · Senate · OK | Purchase | ≥$1K | Mar 27 | Jul 21 |
Ro Khanna Democratic · House · CA-17 | Sale | ≥$1K | Feb 5 | Mar 9 |
Congressional trading data provided by QuiverQuant
How Cardinal Health turned $254B of revenue into $2.6B of operating income.
| Revenue | ||
|---|---|---|
| Pharmaceutical | $235B | ▲ 14.75% YoY |
| GMPD | $12.7B | ▲ 0.66% YoY |
| Other Operating Segment | $6.8B | ▲ 26.20% YoY |
| Total revenue | $254B | |
| Gross profit | $9.8B | 3.8% |
| Operating income | $2.6B | 1.0% |